Life comes at biotech startups fast

Last summer, Compass Therapeutics raised $132 million “to advance its next-generation antibody-based therapeutics into the clinic.” A year later, the company is dosing patients as planned, but it had to lay off 25% of its workforce along the way.

That’s one of many anecdotes in the latest iteration of STAT’s Something Ventured, a series that catches up with biotech startups after the gleam of their financing announcements has faded.

There’s also an update from a company out to build a better nasal spray, one trying to treat hearing loss, and another with a novel way of targeting proteins.

Read more.